Janus Henderson Group PLC Has $3.22 Million Stake in Axsome Therapeutics, Inc. $AXSM

Janus Henderson Group PLC grew its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 26.1% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 19,052 shares of the company’s stock after acquiring an additional 3,948 shares during the quarter. Janus Henderson Group PLC’s holdings in Axsome Therapeutics were worth $3,219,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Wellington Management Group LLP grew its position in shares of Axsome Therapeutics by 84.1% in the 3rd quarter. Wellington Management Group LLP now owns 1,334,560 shares of the company’s stock valued at $162,082,000 after purchasing an additional 609,516 shares during the period. First Trust Advisors LP lifted its stake in Axsome Therapeutics by 1,230.2% in the first quarter. First Trust Advisors LP now owns 577,479 shares of the company’s stock valued at $97,606,000 after buying an additional 534,066 shares in the last quarter. Norges Bank bought a new position in Axsome Therapeutics in the fourth quarter valued at approximately $90,490,000. Price T Rowe Associates Inc. MD boosted its holdings in shares of Axsome Therapeutics by 45.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,509,870 shares of the company’s stock valued at $275,763,000 after buying an additional 472,422 shares during the period. Finally, Invesco Ltd. boosted its holdings in shares of Axsome Therapeutics by 73.3% in the third quarter. Invesco Ltd. now owns 990,557 shares of the company’s stock valued at $120,303,000 after buying an additional 419,008 shares during the period. Institutional investors and hedge funds own 81.49% of the company’s stock.

Insider Buying and Selling at Axsome Therapeutics

In other news, Director Susan Mahony sold 300 shares of the firm’s stock in a transaction dated Tuesday, June 9th. The stock was sold at an average price of $237.21, for a total value of $71,163.00. Following the completion of the transaction, the director owned 1,129 shares in the company, valued at $267,810.09. This trade represents a 20.99% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Mark Coleman sold 6,000 shares of Axsome Therapeutics stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $230.30, for a total value of $1,381,800.00. Following the completion of the sale, the director directly owned 35,140 shares in the company, valued at approximately $8,092,742. This represents a 14.58% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 200,766 shares of company stock valued at $46,685,646. Corporate insiders own 20.60% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on AXSM shares. BMO Capital Markets initiated coverage on shares of Axsome Therapeutics in a report on Monday, July 20th. They set an “outperform” rating and a $310.00 price objective on the stock. Needham & Company LLC upped their target price on shares of Axsome Therapeutics from $225.00 to $255.00 and gave the stock a “buy” rating in a research note on Tuesday, May 5th. UBS Group increased their target price on Axsome Therapeutics from $251.00 to $259.00 and gave the stock a “buy” rating in a report on Friday, April 10th. Cantor Fitzgerald restated an “overweight” rating and issued a $272.00 price target on shares of Axsome Therapeutics in a report on Monday, May 4th. Finally, Wells Fargo & Company boosted their price target on Axsome Therapeutics from $225.00 to $255.00 and gave the company an “overweight” rating in a report on Tuesday, May 5th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $265.55.

Axsome Therapeutics Stock Performance

Shares of AXSM stock opened at $212.74 on Friday. The company’s fifty day simple moving average is $236.95 and its 200-day simple moving average is $203.96. The company has a quick ratio of 1.32, a current ratio of 1.39 and a debt-to-equity ratio of 2.27. The firm has a market cap of $10.95 billion, a PE ratio of -57.03 and a beta of 0.65. Axsome Therapeutics, Inc. has a 12 month low of $102.67 and a 12 month high of $260.19.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.